Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Nov 15, 2017 | SVP, GM - Oncology | Form 4 | Open market or private sale of non-derivative or derivative security | 27,409 | $16.29 | 20,754 | |
| Jul 21, 2021 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 26,189 | -- | 361,272 | |
| Apr 05, 2005 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 26,136 | $4.35 | 26,136 | |
| Apr 05, 2005 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 26,136 | -- | -- | |
| Jul 17, 2019 | EVP and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,621 | -- | 25,621 | |
| May 06, 2005 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,621 | $1.92 | 57,597 | |
| May 06, 2005 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,621 | -- | -- | |
| Oct 30, 2004 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,621 | $1.92 | 126,758 | |
| Jul 07, 2022 | Director, President and CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,123 | -- | 415,887 | |
| Jul 17, 2019 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,104 | -- | 146,580 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.